Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.
Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a trained physician, Maha is a senior leader with extensive pharmaceutical and biotech experience covering clinical development, post-marketing regulatory activities, medical affairs, safety, and reimbursement requirements. Maha is the Chief Medical Officer of Biogen, and in her previous roles, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi,Senior Vice President and Head of Worldwide Medical at Bioverativ Therapeutics Inc., and Head of Europe & Canada Medical and US Medical at Biogen. She has also worked at Bristol Myers Squibb, Cephalon, and United Health Group before first joining Biogen in early 2013.
Maha has significant experience across a broad range of therapeutic areas and disciplines, including the central nervous system (neurology and psychiatry), rheumatology and immunology, rare blood disorders, ophthalmology, cardiology, diabetes, and internal medicine.
Natalie Yivgi Ohana, Co-Founder and CEO Minovia Therapeutics, said, “Mitochondrial diseases are often fatal and currently viewed as untreatable, something we are working relentlessly to change. So far twelve patients suffering Primary Mitochondrial Diseases were dosed with our Mitochondrial Augmentation Technology, both through compassionate use program and a Phase 1/2 trial in Israel. Minovia Invested greatly in research and development in the last two years, establishing strong scientific and GMP foundations, which will enable us to seek approval for Pearson Syndrome and expand to other disease areas. As board member at Minovia, we will be able to draw on Maha’s considerable medical, regulatory and drug development expertise and experience in bringing successful treatments to patients with primary and secondary mitochondrial diseases.”
Maha added: “Minovia is changing the way we look at mitochondrial therapies. They are on the precipice of meaningfully and measurably improving the lives of patients in need. I look forward to providing oversight and helping Minovia achieve its goals to approve their novel mitochondrial cell therapies in multiple disease areas.”
The appointment of Maha as a board member follows on from Minovia’s recent partnership with Astellas Pharma to develop novel Mitochondrial Cell Therapies, as well as the initial data publication in Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.abo3724).
About Minovia Therapeutics
Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat patients affected with mitochondrial diseases through its Mitochondrial Augmentation Technology (MAT) platform. MAT is being developed as a robust and scalable therapeutic platform targeting the root cause of diseases generated by mitochondrial dysfunction. The lead product, MNV-201 is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia’s initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments in the United States and the unmet medical need is immense. After completing an IND enabled phase I/II clinical trial in Pearson Syndrome, a fatal pediatric disease, Minovia is planning to accelerate the clinical development for Pearson Syndrome and expand the pipeline to other Hematological/Mitochondrial-related diseases. Harnessing the power of mitochondria, Minovia is committed to exploring the full potential of its proprietary platform to address mitochondrial diseases ranging from orphan indications to more common and age-related diseases.
For more information, please visit http://minoviatx.com/.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Zoom to Release Financial Results for the Fourth Quarter and Full Fiscal Year 20231.2.2023 22:05:00 CET | Press release
SAN JOSE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the fourth quarter and full fiscal year 2023 on Monday, February 27, 2023, after the market closes. A live Zoom Video Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event. About Zoom Zoom is for you. Zoom is a space where you can connect to others, share ideas, make plans, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and
CORRECTION: Boyden Appoints Distinguished Talent Solutions Leader Chad Hesters President & CEO1.2.2023 20:23:02 CET | Press release
Succession planning for Trina Gordon’s retirement, led by Chairman Craig Stevens, results in marquee hire Chad Hesters New York, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Correction: The original hyperline for "Chad Hesters" was incorrect. This has been rectified. Boyden, a premier leadership and talent advisory firm with more than 70 offices in over 45 countries, is delighted to announce the appointment of Chad Hesters as President & CEO, effective immediately. He takes the reins from Trina Gordon, who retires after 12 years as CEO, 3 years as Chair, and 30+ years as a Managing Partner in the firm. “I am honored to be appointed President & CEO of Boyden,” commented Chad Hesters. “I have long admired Trina Gordon for her leadership and her custodianship of one of the oldest, global heritage brands in our industry. Boyden has a unique, collaborative culture that puts clients at the heart of their business. This collegial community is distinctive and aligns well with my style of engagement in th
Nokia Corporation: Repurchase of own shares on 01.02.20231.2.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 1 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 01.02.2023 Espoo, Finland – On 1 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL267,9884.36CEUX32,5604.36AQEU11,2214.35TQEX4,1314.36Total315,9004.36 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 202
HqO Releases 2023 ‘The State of Workplace Experience’ Report1.2.2023 19:18:11 CET | Press release
New research measures shifts in employee sentiment post-pandemic, emphasizing importance of social infrastructure in the workplace BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- HqO, the world’s leading workplace experience platform, today announced the release of its annual “The State of Workplace Experience” report, a research-driven analysis of how the workplace and overall employee sentiment have evolved over the past year and what trends will emerge in 2023 as more workers are called back to the office. Featuring proprietary data from research firms Gartner and Leesman, an HqO company, the 2023 report details a shift in how employees perceive and use the workplace, from an environment where the full scope of their work gets done – focused and individual activities, as well as group meetings – to a space that supports more spontaneous collaboration and interaction. Highlights include: From before the start of the pandemic to 2021-22, the percentage of respondents who said informal socia
REPURCHASE OF SHARES1.2.2023 18:30:00 CET | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders Ltd. (“Flow Traders”) (Euronext: FLOW) has repurchased50,431of its own shares in the period from 26 January 2023 up to and including1February 2023 at an average price of €23.41. This is in accordance with the share buyback program originally announced on 22 July 2022 and subsequently increased as per the announcement made on 27 October 2022. The consideration of this purchase was €1.2 million. The total number of shares purchased under this program to date is 1,137,890 shares at an average price of €21.29 for a total consideration of €24.2 million. 3,491,110 shares were held in treasury as at 1 February 2023. Contact Details Flow Traders Ltd. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996149 Email: email@example.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (